Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.69 |
| ▸ | CLK2 | P49760 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105668 | 0.91 | BTK (0.83) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL13894111 | 0.88 | BTK (0.53) | BTKCLK2 | |
| SCHEMBL105365 | 0.85 | BTK (0.69) | BTKCLK2EGFRBMXJAK3 | |
| SCHEMBL3868632 | 0.85 | BTK (0.72) | BTKCLK2BMX | |
| SCHEMBL3867905 | 0.85 | BTK (0.72) | BTKCLK2BMX | |
| SCHEMBL3866373 | 0.83 | BTK (0.88) | BTKCLK2 | |
| SCHEMBL3869783 | 0.83 | BTK (0.82) | BTKCLK2 | |
| SCHEMBL3867480 | 0.82 | BTK (0.88) | BTKCLK2 | |
| SCHEMBL3870986 | 0.82 | BTK (0.86) | BTKCLK2 | |
| SCHEMBL3867945 | 0.82 | BTK (0.86) | BTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | BTK 1/4885CLK2 552/4885EGFR 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.